Peer support may lift the cloud of loneliness for older gay men with HIV

NCT ID NCT07762066

Recruiting now Symptom relief Sponsor: Fenway Community Health Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests a 10-session peer-led program called Bridge to Belonging, designed to reduce loneliness and depression in older gay and bisexual men living with HIV. The program uses group sessions to build social skills and connect participants with LGBTQ+-affirming community services. Researchers will see if the program is feasible and acceptable, and whether it shows promise in improving mood and social connection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A 10-session peer-delivered group program combining cognitive behavioral therapy-based social skills training and peer mentoring to encourage engagement in LGBTQ+-affirming community services.
What this could lead to: If successful, this could point toward a scalable, peer-led way to ease loneliness and depression in older gay and bisexual men living with HIV, improving their overall well-being.
What could go wrong: This is a small early feasibility study, not a large effectiveness trial, so results may not generalize. The program's impact on depression and loneliness is still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Fenway Health
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.